Non-Viral Transfection Reagents and Systems Market, 2020-2030

Non-Viral Transfection Reagents and Systems Market, 2020-2030

Over the last few years, the exponential growth in the pipeline of nucleic acid based therapies has led to the escalating interest of pharmaceutical industry in this domain. Presently, more than 2,000 trials evaluating different types of gene therapies are underway. Moreover, according to experts at the US FDA, around 40 new gene therapies are likely to be approved by 2022. In this context, it is worth highlighting that viral vectors are a crucial element in gene therapy development and manufacturing. Although, viral vectors have shown significant success in R&D, their applications are limited due to immunogenicity and toxicity related concerns, high development costs and the limitation on amount of genomic material that they can carry. Excessively high price tags associated with viral-based therapies, such as Zolgensma® (USD 2.1 million) and Luxtruna® (USD 850,000), have led to several reimbursement challenges, thereby decreasing patient access. Owing to the aforementioned concerns related to viral vectors, therapy developers are evaluating a variety of non-viral methods of gene delivery.

In the present scenario, non-viral transfection systems are not yet widely used in therapy development and clinical studies, primarily due to their relatively low efficiency compared to viruses. The applications of these methods are largely restricted to fundamental research, including protein and gene expression, and cell line development. However, there are a number of companies that have developed proprietary technologies and products to facilitate physical (electroporation, gene gun, microinjection and sonoporation), chemical (transfection reagents) and other non-viral methods of transfection (transposon based systems, piggyBac and magnetofection). We believe that, as the demand for advanced therapy medicinal products, which require genetic engineering, the opportunity for non-viral transfection system developers is also likely to grow.

SCOPE OF THE REPORT
The ‘Non-Viral Transfection Reagents and Systems Market, 2020-2030’ report features an extensive study of the various systems and technologies available for non-viral transfection, in addition to the current market landscape and future potential of product developers. Amongst other elements, the report features:
 A detailed assessment of the competitive landscape of various types of non-viral transfection systems, including transfection reagents, electroporation-based transfection systems and other non-viral transfection systems, featuring product specific information, such as type of carrier used, type of molecule delivered, recommended cell type and price of the system (if available). Additionally, the chapter includes information on non-viral transfection system developers, including information on year of establishment, company size and geographical location.
 An insightful 2X2 representation, highlighting the competitiveness analysis of non-viral transfection system developers captured in our database, taking into consideration supplier power (based on company size) and service strength (based on strength of product portfolio, years of experience and type of molecule delivered).
 An analysis highlighting potential strategic partners segregated based on likelihood of entering into collaboration with non-viral transfection system developers. The analysis takes into consideration multiple relevant parameters, such as type of therapy, pipeline strength, pipeline maturity, type of vector and company size.
 An analysis of the big pharma players engaged in this domain, featuring a heat map based on parameters, such as type of initiative, type of therapy and target therapeutic area.
 An analysis of completed, ongoing and planned clinical studies related to non-viral transfection systems, featuring details on registration year, trial phase, trial status, type of sponsor, type of therapy, target therapeutic area, trial design, type of patient allocation model used, type of trial masking adopted, type of intervention, trial purpose, geographical location of trial and enrolled patient population.
 An in-depth analysis of close to 14,000 patents related to non-viral transfection systems that have been filed / granted since 2017, highlighting key trends associated with these patents, across type of patents, publication year, geographical location, type of applicants, issuing authority / patent offices involved, CPC symbols, emerging focus areas, leading players (in terms of number of patents granted / filed in the given time period), patent characteristics and geography. It also includes a detailed patent benchmarking and an insightful valuation analysis.
 A detailed publication analysis of more than 1,100 peer-reviewed, scientific articles that have been published since 2014, highlighting the key trends associated with these publications, across year of publication, focus area, type of molecule delivered, target therapeutic area, important cells and cell lines evaluated, leading players across different geographies and key journals (in terms of number of articles published in the given time period) within this domain.

One of the key objectives of the report was to understand the primary growth drivers and estimate the future opportunity within the market. Based on several parameters, such as annual number of transfections, cost per transfection, share of non-viral systems within the transfections market and expected annual growth rate across various geographies, we have provided an informed estimate of the likely evolution of the market, in the mid to long term, for the period 2020-2030. The chapter features the likely distribution of the future opportunity across [A] non-viral transfection systems (non-viral transfection reagents, electroporation-based transfection systems and other non-viral transfection systems), [B] end-users (academic and research institutions, pharmaceutical companies and other end-users), [C] area of application (clinical application and research application) and [D] geographical regions (North America, Europe, Asia-Pacific and rest of the world).

In order to account for future uncertainties and to add robustness to our model, we have provided three forecast scenarios, portraying the conservative, base and optimistic tracks of the market’s evolution. The opinions and insights presented in this study were influenced by discussions conducted with multiple stakeholders in this domain. In addition, the report features detailed transcripts of interviews held with the following individuals (in alphabetical order of company names):
 George Eastwood (Vice-President of Business Development, Kytopen)
 Claudia Andretta (Global Business Development Manager, Clinical, Polyplus-transfection)

All actual figures have been sourced and analyzed from publicly available information forums. Financial figures mentioned in this report are in USD, unless otherwise specified.

RESEARCH METHODOLOGY
The research, analysis and insights presented in this report are backed by a deep understanding of insights gathered from both secondary and primary sources. For all our projects, we conduct interviews with experts in the area (academia, industry and other associations) to solicit their opinions on emerging trends in the market. This is primarily useful for us to draw out our own opinion on how the market will evolve across different regions and technology segments. Where possible, the available data has been checked for accuracy from multiple sources of information.

The secondary sources of information include
 Annual reports
 Investor presentations
 SEC filings
 Industry databases
 News releases from company websites
 Government policy documents
 Industry analysts’ views

While the focus has been on forecasting the market till 2030, the report also provides our independent view on various non-commercial trends emerging in the industry. This opinion is solely based on our knowledge, research and understanding of the relevant market gathered from various secondary and primary sources of information.

CHAPTER OUTLINES
Chapter 2 is an executive summary of the insights captured in our research. It offers a high-level view on the likely evolution of the non-viral transfection systems market in the mid to long term.

Chapter 3 provides an overview of transfection and its applications, such as advanced therapy medicinal product development, gene silencing, bioproduction of therapeutic protein and stem cell engineering. It highlights different methods of transfection (such as viral and non-viral), with a brief outline of various viral vectors (AAV, adenoviral, lentiviral, retroviral and others), chemical methods (lipoplexes, polyplexes, lipoplexes and others) and physical methods (electroporation, gene gun, sonoporation, magnetofection and others) used in transfection.

Chapter 4 provides an overview of various types of non-viral transfection systems including transfection reagents, electroporation-based transfection systems and other non-viral transfection systems, featuring product specific information, such as type of carrier used, type of molecule delivered, recommended cell type and price of the system (if available). Additionally, the chapter includes information on non-viral transfection system developers, including information on year of establishment, company size and geographical location.

Chapter 5 provides a detailed competitiveness analysis of the companies offering non-viral transfection systems, taking into consideration supplier power (based on company size) and service strength (based on strength of product portfolio, years of experience and type of molecule delivered).

Chapter 6 includes detailed profiles of prominent transfection reagent developers, electroporation-based transfection system developers and other non-viral delivery system developers, featuring a brief overview of the company, its financial information (if available), recent developments and an informed future outlook.

Chapter 7 features an insightful analysis, highlighting potential strategic partners, based on likelihood of entering into collaboration with non-viral transfection system developers, taking into account several parameters, such as type of therapy, pipeline strength, pipeline maturity, company size and type of vector.

Chapter 8 highlights the activity of top ten big pharma players in this domain, featuring a heat map based on parameters, such as such as type of initiative, type of therapy and target therapeutic area.

Chapter 9 provides an analysis of completed, ongoing and planned clinical studies related to non-viral transfection systems, featuring details on registration year, trial phase, trial status, type of sponsor, type of therapy, target therapeutic area, trial design, type of patient allocation model used, type of trial masking adopted, type of intervention, trial purpose, geographical location of trial and enrolled patient population.

Chapter 10 provides an in-depth patent analysis to provide an overview of how the industry is evolving from the R&D perspective. For this analysis, we considered those patents that have been filed / granted related to non-viral transfection systems, since 2017, highlighting key trends associated with these patents, across type of patents, publication year, geographical location, type of applicants, issuing authority / patent offices involved, CPC symbols, emerging focus areas, leading players (in terms of number of patents granted / filed in the given time period), patent characteristics and geography. It also includes a detailed patent benchmarking and an insightful valuation analysis.

Chapter 11 presents a detailed publication analysis of more than 1,100 peer-reviewed, scientific articles that have been published since 2014, highlighting the key trends associated with these publications, across year of publication, focus area, type of molecule delivered, target therapeutic area, important cells and cell lines evaluated, leading players across different geographies and key journals (in terms of number of articles published in the given time period) within this domain.

Chapter 12 presents a detailed market forecast, highlighting the future potential of the non-viral transfection systems market till the year 2030. The chapter features the likely distribution of the opportunity across different [A] non-viral transfection methods (non-viral transfection reagents, electroporation-based transfection systems and other non-viral transfection systems), [B] end-users (academic and research institutions, pharmaceutical companies and other end-users), [C] area of application (clinical application and research application) and [D] geographical regions (North America, Europe, Asia-Pacific and rest of the world).

Chapter 13 is a collection of executive insights of the discussions that were held with various key stakeholders in this market. The chapter provides a brief overview of the companies and details of interviews held with George Eastwood (Vice-President of Business Development, Kytopen) and Claudia Andretta (Global Business Development Manager, Clinical, Polyplus-transfection).

Chapter 14 summarizes the entire report. It presents a list of key takeaways and offers our independent opinion on the current market scenario. Further, it summarizes the various evolutionary trends that are likely to influence the future of this market.

Chapter 15 is an appendix, which provides tabulated data and numbers for all the figures included in the report.

Chapter 16 is an appendix, which contains the list of companies and organizations mentioned in the report.

LIST OF COMPANIES / LIST OF COMPANIES AND ORGANIZATIONS

The following companies and organizations have been mentioned in the report.
1. 10x Genomics
2. 20Med Therapeutics
3. AAT Bioquest
4. Abbiotec
5. Applied Biological Materials
6. Acuitas Therapeutics
7. Agilent Technologies
8. Allergan
9. Altogen Biosystems
10. AstraZeneca
11. Avanti Polar Lipids
12. Avectus Healthcare Solutions
13. BEX
14. Bio Basic
15. Biotechnologies
16. Biomaterials USA
17. BioNTech Protein
18. Biontex Laboratories
19. Biopact
20. Bio-Rad Laboratories
21. BIOTOOLS
22. BioWare Technologies
23. Bristol-Myers Squibb
24. Broad Institute
25. BTX
26. Canvax
27. Caribou Biosciences
28. Casebia Therapeutics
29. Celetrix
30. Cell and Gene Therapy Catapult
31. Cell Applications
32. Cellectis
33. Celsion Corporation
34. Chinese University of Hong Kong
35. Cosmo Bio
36. Creative Biolabs
37. CRISPR Therapeutics
38. Cybrexa Therapeutics
39. Danisco
40. Drummond Scientific
41. Editas Medicine
42. Eli Lilly
43. Emisphere Technologies
44. enGene
45. Enzo Life Sciences
46. Eppendorf
47. Exicure
48. Exon Biosciences
49. ExpreS2ion Biotechnologies
50. Eyevensys
51. EZ Biosystems
52. Feldan Therapeutics
53. FormuMax Scientific
54. Fuda Cancer Hospital
55. Fugent
56. FUJIFILM Irvine Scientific
57. G-Biosciences
58. Gemini Bio-Products
59. GeneCopoeia
60. GeneDireX
61. GeneOne Life Science
62. Genlantis
63. Genprex
64. GenScript
65. Gilead Sciences
66. GlaxoSmithKline
67. Gradalis
68. Harvard College
69. Helixmith
70. Horizon Discovery
71. Ichor Medical Systems
72. Icosagen
73. IGEA
74. Immudicon
75. In-Cell-Art
76. indee labs
77. Infinitesimal
78. Inovio Pharmaceuticals
79. Inserm
80. iNtRON Biotechnology
81. InvivoGen
82. Ionis Pharmaceuticals
83. Janssen Pharmaceutica
84. KSQ Therapeutics
85. Kytopen
86. Lemonex
87. Locate Bio
88. Lonza
89. Massachusetts Institute of Technology
90. MaxCyte
91. Merck
92. MilliporeSigma
93. Miltenyi Biotec
94. Mirai Medical
95. Mirus Bio
96. Moderna
97. N4 Pharma
98. nanoTherics
99. Narishige
100. National Cancer Institute
101. National Institute of Allergy and Infectious Diseases
102. NepaGene
103. Neuromics
104. NGM Biopharmaceuticals
105. Ningbo Scientz Biotechnology
106. Novartis
107. Novo Nordisk
108. Novozymes
109. NTrans Technologies
110. OpenCell Technologies
111. OrganoLinX
112. OriGene Technologies
113. OZ Biosciences
114. Pfizer
115. pHion Therapeutics
116. Plexxikon
117. Polyplus-transfection
118. Polysciences
119. Poseida Therapeutics
120. Precigen
121. Precision Bio Laboratories
122. Precision BioSciences
123. Precision NanoSystems
124. Promega Corporation
125. PromoCell
126. Proteacel
127. Qiagen
128. Regeneron Pharmaceuticals
129. RJH Biosciences
130. Roche
131. Sanofi
132. Santa Cruz Biotechnology
133. Scinogy
134. ScreenFect
135. SignaGen Laboratories
136. Sino Biological
137. SQZ Biotech
138. Stanford University
139. Stoelting
140. Sutter Instrument
141. Synvolux Products
142. System Biosciences
143. Taipei Veterans General Hospital
144. Takara Bio
145. Tecrea
146. Thermo Fisher Scientific
147. Torque Pharmaceuticals
148. Touchlight Genetics
149. T-Pro Biotechnology
150. transOMIC technologies
151. Tritech Research
152. University of Pittsburgh
153. University of Texas
154. Vor Biopharma
155. Wealtec Bioscience


1. PREFACE
1.1. Scope of the Report
1.2. Research Methodology
1.3. Chapter Outlines
2. EXECUTIVE SUMMARY
3. INTRODUCTION
3.1. Chapter Overview
3.2. Overview of Transfection
3.3. Applications of Transfection
3.3.1. Advanced Therapy Medicinal Product Development
3.3.2. Gene Silencing
3.3.3. Generation of Stable Cell Lines
3.3.4. Large-scale Protein Production
3.3.5. Stem Cell Engineering
3.4. Methods of Transfection
3.4.1. Viral Transfection
3.4.1.1. Types of Viral Vectors
3.4.1.1.1. Adeno-associated Vector
3.4.1.1.2. Adenoviral Vector
3.4.1.1.3. Herpes Virus
3.4.1.1.4. Lentiviral
3.4.1.1.5. Retroviral
3.4.2. Non-Viral Transfection
3.4.2.1. Chemical Methods
3.4.2.1.1. Lipoplexes
3.4.2.1.2. Polyplexes
3.4.2.1.3. Lipo-polyplexes
3.4.2.1.4. Dendrimers
3.4.2.1.5. Cell Penetrating Peptides
3.4.2.2. Physical Methods
3.4.2.2.1. Electroporation
3.4.2.2.2. Gene Gun
3.4.2.2.3. Sonoporation
3.4.2.2.4. Microinjection
3.4.2.2.5. Magnetofection
3.5. Future Perspectives
4. MARKET LANDSCAPE: NON-VIRAL TRANSFECTION
SYSTEMS
4.1. Chapter Overview
4.2. Non-Viral Transfection Reagents: Market Landscape
4.2.1.1. Analysis by Type of Carrier Used
4.2.1.2. Analysis by Type of Molecule Delivered
4.2.1.3. Analysis of Developers by Year of Establishment
4.2.1.4. Analysis of Developers by Company Size
4.2.1.5. Analysis of Developers by Geography
4.3. Electroporation-based Transfection Systems: Market Landscape
4.3.1.1. Analysis by Type of Molecule Delivered
4.3.1.2. Analysis by Compatible Cell Type
4.3.1.3. Analysis of Developers by Year of Establishment
4.3.1.4. Analysis of Developers by Company Size
4.3.1.5. Analysis of Developers by Geography
4.4. Other Non-Viral Transfection Systems: Market Landscape
4.4.1.1. Analysis by Type of Molecule Delivered
4.4.1.2. Analysis by Compatible Cell Type
4.4.1.3. Analysis of Developers by Year of Establishment
4.4.1.4. Analysis of Developers by Company Size
4.4.1.5. Analysis of Developers by Geography
5. NON-VIRAL TRANSFECTION SYSTEMS: COMPANY
COMPETITIVENESS ANALYSIS
5.1. Chapter Overview
5.2. Methodology and Key Parameters
5.3. Competitiveness Analysis: Transfection Reagent Providers
5.3.1. Competitiveness Analysis: Transfection Reagent Providers based in
North America
5.3.2. Competitiveness Analysis: Transfection Reagent Providers based in
Europe
5.3.3. Competitiveness Analysis: Transfection Reagent Providers based in
Asia-Pacific
5.4. Competitiveness Analysis: Electroporation-based Transfection System Providers
6. COMPANY PROFILES
6.1. Chapter Overview
6.2. Transfection Reagent Providers
6.2.1. Altogen Biosystems
6.2.1.1. Company Overview
6.2.1.2. Recent Developments and Future Outlook
6.2.2. MilliporeSigma
6.2.2.1. Company Overview
6.2.2.2. Financial Information
6.2.2.3. Recent Developments and Future Outlook
6.2.3. OZ Biosciences
6.2.3.1. Company Overview
6.2.3.2. Recent Developments and Future Outlook
6.2.4. Thermo Fisher Scientific
6.2.4.1. Company Overview
6.2.4.2. Financial Information
6.2.4.3. Recent Development and Future Outlook
6.3. Gene Gun-based Transfection System Providers
6.3.1. Bio-Rad Laboratories
6.3.1.1. Company Overview
6.3.1.2. Financial Information
6.3.1.3. Recent Developments and Future Outlook
6.3.2. Ningbo Scientz Biotechnology
6.3.2.1. Company Overview
6.4. Electroporation-based Transfection System Providers
6.4.1. BEX
6.4.1.1. Company Overview
6.4.2. BTX (Harvard Bioscience Division)
6.4.2.1. Company Overview
6.4.2.2. Recent Developments and Future Outlook
6.4.3. MaxCyte
6.4.3.1. Company Overview
6.4.3.2. Financial Information
6.4.3.3. Recent Developments and Future Outlook
6.4.4. NepaGene
6.4.4.1. Company Overview
6.5. Other Non-Viral Transfection System Providers
6.5.1. Celsion Corporation
6.5.1.1. Company Overview
6.5.1.2. Recent Developments and Future Outlook
6.5.2. Genprex
6.5.2.1. Company Overview
6.5.2.2. Financial Information
6.5.2.3. Recent Developments and Future Outlook
6.5.3. Inovio Pharmaceuticals
6.5.3.1. Company Overview
6.5.3.2. Financial Information
6.5.3.3. Recent Developments and Future Outlook
7. POTENTIAL STRATEGIC PARTNERS
7.1. Chapter Overview
7.2. Scope and Methodology
7.3. Potential Strategic Partners for Non-Viral Transfection System Providers
in North America
7.3.1.1. Key Industry Partners
7.3.2. Key Non-Industry / Academic Partners
7.4. Potential Strategic Partners for Non-Viral Transfection System Providers
in Europe
7.4.1.1. Key Industry Partners
7.4.2. Key Non-Industry / Academic Partners
7.5. Potential Strategic Partners for Non-Viral Transfection System Providers
in Asia-Pacific
7.5.1.1. Key Industry Partners
7.5.2. Key Non-Industry / Academic Partners
8. BIG PHARMA INITIATIVES
8.1. Chapter Overview
8.2. Scope and Methodology
8.2.1. Analysis by Type of Initiative
8.2.2. Analysis by Type of Therapy
8.2.3. Analysis by Therapeutic Area
9. CLINICAL TRIAL ANALYSIS
9.1. Chapter Overview
9.2. Scope and Methodology
9.3. Non-Viral Transfection Systems: Clinical Trials Analysis
9.3.1. Analysis by Trial Registration Year
9.3.2. Analysis by Trial Phase
9.3.3. Analysis by Trial Status
9.3.4. Analysis by Type of Sponsor
9.3.5. Analysis by Type of Therapy
9.3.6. Analysis by Target Therapeutic Area
9.3.7. Analysis by Trial Design
9.3.8. Analysis by Type of Patient Allocation Model Used
9.3.9. Analysis by Type of Masking Adopted
9.3.10. Analysis by Type of Intervention
9.3.11. Analysis by Trial Purpose
9.3.12. Analysis by Number of Trials and Geographical Location
9.3.13. Analysis by Enrolled Patient Population and Geographical Location
9.3.14. Analysis by Number of Trials, Trial Status and Geographical Location
9.3.15. Analysis by Enrolled Patient Population, Trial Status and Geographical Location
10. PATENT ANALYSIS
10.1. Chapter Overview
10.2. Key Parameters and Methodology
10.3. Non-Viral Transfection Systems: Patent Analysis
10.3.1. Analysis by Publication Year
10.3.2. Analysis by Geographical Location
10.3.3. Analysis by Type of Applicant
10.3.4. Analysis by CPC Symbol
10.3.5. Word Cloud: Emerging Focus Areas
10.3.6. Leading Players: Analysis by Number of Patents
10.4. Non-Viral Transfection Systems: Patent Benchmarking Analysis
10.4.1. Analysis by Patent Characteristics
10.4.2. Analysis by Geography
10.5. Non-Viral Transfection Systems: Patent Valuation Analysis
11. PUBLICATION ANALYSIS
11.1. Chapter Overview
11.2. Scope and Methodology
11.3. Analysis by Year of Publication
11.4. Analysis by Publication Focus
11.5. Analysis by Type of Molecule Delivered
11.6. Analysis by Target Therapeutic Area
11.7. Word Cloud: Important Cells and Cell Lines
11.8. Leading Players: Geographical Analysis by Number of Publications
11.9. Key Journals: Analysis by Number of Publications
12. MARKET FORECAST
12.1. Chapter Overview
12.2. Forecast Methodology and Key Assumptions
12.3. Overall Non-Viral Transfection Systems Market, 2020-2030
12.4. Non-Viral Transfection Systems Market: Distribution by Transfection Method, 2020 and 2030
12.5. Non-Viral Transfection Systems Market: Distribution by End-User, 2020
and 2030
12.6. Non-Viral Transfection Systems Market: Distribution by Area of Application 2020 and 2030
12.7. Non-Viral Transfection Systems Market: Distribution by Regions, 2020
and 2030
12.7.1. Non-Viral Transfection Systems Market in North America, 2020-2030
12.7.1.1. Non-Viral Transfection Systems Market in North America, Distribution
by End-User
12.7.1.1.1. Non-Viral Transfection Systems Market in North America: Share of
Pharmaceutical Companies, 2020-2030
12.7.1.1.2. Non-Viral Transfection Systems Market in North America: Share of Academic and Research Institutions, 2020-2030
12.7.1.1.3. Non-Viral Transfection Systems Market in North America: Share of Other
End-Users, 2020-2030
12.7.1.2. Non-Viral Transfection Systems Market in North America, Distribution
by Area of Application
12.7.1.2.1. Non-Viral Transfection Systems Market in North America for Research
Application, 2020-2030
12.7.1.2.2. Non-Viral Transfection Systems Market in North America for Clinical
Application, 2020-2030
12.7.2. Non-Viral Transfection Systems Market in Europe, 2020-2030
12.7.2.1. Non-Viral Transfection Systems Market in Europe, Distribution by End-
User
12.7.2.1.1. Non-Viral Transfection Systems Market in Europe: Share of Pharmaceutical Companies, 2020-2030
12.7.2.1.2. Non-Viral Transfection Systems Market in Europe: Share of Academic and Research Institutions, 2020-2030
12.7.2.1.3. Non-Viral Transfection Systems Market in Europe: Share of Other End-Users, 2020-2030
12.7.2.2. Non-Viral Transfection Systems Market in Europe, Distribution by
Area of Application
12.7.2.2.1. Non-Viral Transfection Systems Market in Europe for Research
Application, 2020-2030
12.7.2.2.2. Non-Viral Transfection Systems Market in Europe for Clinical
Application, 2020-2030
12.7.3. Non-Viral Transfection Systems Market in Asia-Pacific, 2020-2030
12.7.3.1. Non-Viral Transfection Systems Market in Asia-Pacific, Distribution by
End-User
12.7.3.1.1. Non-Viral Transfection Systems Market in Asia-Pacific: Share of
Pharmaceutical Companies, 2020-2030
12.7.3.1.2. Non-Viral Transfection Systems Market in Asia-Pacific: Share of Academic and Research Institutions, 2020-2030
12.7.3.1.3. Non-Viral Transfection Systems Market in Asia-Pacific: Share of Other End-Users, 2020-2030
12.7.3.2. Non-Viral Transfection Systems Market in Asia-Pacific, Distribution by
Area of Application
12.7.3.2.1. Non-Viral Transfection Systems Market in Asia-Pacific for Research
Application, 2020-2030
12.7.3.2.2. Non-Viral Transfection Systems Market in Asia-Pacific for Clinical
Application, 2020-2030
12.7.4. Non-Viral Transfection Systems Market in Rest of the World, 2020-2030
12.7.4.1. Non-Viral Transfection Systems Market in Rest of the World,
Distribution by End-User
12.7.4.1.1. Non-Viral Transfection Systems Market in Rest of the World: Share of
Pharmaceutical Companies, 2020-2030
12.7.4.1.2. Non-Viral Transfection Systems Market in Rest of the World: Share of
Academic and Research Institutions, 2020-2030
12.7.4.1.3. Non-Viral Transfection Systems Market in Rest of the World: Share of Other End-Users, 2020-2030
12.7.4.2. Non-Viral Transfection Systems Market in Rest of the World,
Distribution by Area of Application
12.7.4.2.1. Non-Viral Transfection Systems Market in Rest of the World for Research
Application, 2020-2030
12.7.4.2.2. Non-Viral Transfection Systems Market in Rest of the World for Clinical Application, 2020-2030
13. EXECUTIVE INSIGHTS
13.1. Chapter Overview
13.2. Kytopen
13.2.1. Interview Transcript: George Eastwood, Vice-President Business
Development
13.3. Polyplus-transfection
13.3.1. Interview Transcript: Claudia Andretta, Global Business Development
Manager, Clinical
14. CONCLUSION
15. APPENDIX 1: TABULATED DATA
16. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS
LIST OF FIGURES
Figure 3.1 Applications of Transfection
Figure 3.2 Commonly Used Viral Vectors
Figure 3.3 Types of Non-Viral Transfection Methods
Figure 3.4 Electroporation Mechanism
Figure 3.5 Gene Gun Mechanism
Figure 3.6 Sonoporation Mechanism
Figure 3.7 Microinjection Mechanism
Figure 3.8 Magnetofection Mechanism
Figure 4.1 Non-Viral Transfection Reagents: Distribution by Type of Carrier Used
Figure 4.2 Non-Viral Transfection Reagents: Distribution by Type of Molecule Delivered
Figure 4.3 Non-Viral Transfection Reagent Developers: Distribution by Year of Establishment
Figure 4.4 Non-Viral Transfection Reagent Developers: Distribution by Company Size
Figure 4.5 Non-Viral Transfection Reagent Developers: Distribution by Geography
Figure 4.6 Electroporation-based Transfection Systems: Distribution by Type of Molecule Delivered
Figure 4.7 Electroporation-based Transfection Systems: Distribution by Compatible Cell Type
Figure 4.8 Electroporation-based Transfection System Developers: Distribution by Year of Establishment
Figure 4.9 Electroporation-based Transfection System Developers: Distribution by Company Size
Figure 4.10 Electroporation-based Transfection System Developers: Distribution by Geography
Figure 4.11 Other Non-Viral Transfection Systems: Distribution by Type of
Molecule Delivered
Figure 4.12 Other Non-Viral Transfection Systems: Distribution by Compatible Cell Type
Figure 4.13 Other Non-Viral Transfection System Developers: Distribution by Year of
Establishment
Figure 4.14 Other Non-Viral Transfection System Developers: Distribution by Company
Size
Figure 4.15 Other Non-Viral Transfection System Developers: Distribution by Geography
Figure 5.1 Competitiveness Analysis: Transfection Reagent Providers based in North America
Figure 5.2 Competitiveness Analysis: Transfection Reagent Providers based in Europe
Figure 5.3 Competitiveness Analysis: Transfection Reagent Providers based in Asia-Pacific
Figure 5.4 Competitiveness Analysis: Electroporation-based Transfection System Providers
Figure 6.1 MilliporeSigma: Annual Revenues, 2013-Q3 2019 (USD Million)
Figure 6.2 Thermo Fisher Scientific: Annual Revenues, 2013-2019 (USD Billion)
Figure 6.3 Bio-Rad Laboratories: Annual Revenues, 2013- Q3 2019 (USD Million)
Figure 6.4 MaxCyte: Annual Revenues, 2013-H1 2019 (USD Million)
Figure 6.5 Genprex: Annual Revenues, 2013-Q3 2019 (USD Million)
Figure 6.6 Inovio Pharmaceuticals: Annual Revenues, 2013-Q3 2019 (USD Million)
Figure 8.1 Big Pharma Initiatives: Distribution by Type of Initiative
Figure 8.2 Big Pharma Initiatives: Distribution by Type of Therapy
Figure 8.3 Big Pharma Initiatives: Distribution by Therapeutic Area
Figure 9.1 Clinical Trial Analysis: Distribution by Trial Registration Year
Figure 9.2 Clinical Trial Analysis: Distribution by Enrolled Patient Population and Trial
Registration Year
Figure 9.3 Clinical Trial Analysis: Distribution by Trial Phase
Figure 9.4 Clinical Trial Analysis: Distribution by Trial Status
Figure 9.5 Clinical Trial Analysis: Distribution by Type of Sponsor
Figure 9.6 Clinical Trial Analysis: Distribution by Type of Therapy
Figure 9.7 Clinical Trial Analysis: Distribution by Target Therapeutic Area
Figure 9.8 Clinical Trial Analysis: Distribution by Trial Design
Figure 9.9 Clinical Trial Analysis: Distribution by Type of Patient Allocation Model Used
Figure 9.10 Clinical Trial Analysis: Distribution by Type of Masking Adopted
Figure 9.11 Clinical Trial Analysis: Distribution by Type of Intervention
Figure 9.12 Clinical Trial Analysis: Distribution by Trial Purpose
Figure 9.13 Clinical Trial Analysis: Distribution by Number of Trials and Geographical Location
Figure 9.14 Clinical Trial Analysis: Distribution by Enrolled Patient Population and Geographical Location
Figure 9.15 Clinical Trial Analysis: Distribution by Number of Trials, Trial Status and
Geographical Location
Figure 9.16 Clinical Trial Analysis: Distribution by Enrolled Patient Population, Trial Status
and Geographical Location
Figure 10.1 Patent Portfolio: Distribution by Patent Type
Figure 10.2 Patent Portfolio: Cumulative Distribution by Publication Year, 2017-2019
Figure 10.3 Patent Portfolio: Distribution by Geographical Location and Publication Year
Figure 10.4 Patent Portfolio: Distribution by Patent Type and Publication Year
Figure 10.5 Patent Portfolio: Distribution by Geographical Location
Figure 10.6 Patent Portfolio: Distribution by Jurisdiction
Figure 10.7 Patent Portfolio: Cumulative Year-wise Distribution by Type of Applicant
Figure 10.8 Patent Portfolio: Distribution by CPC Symbols
Figure 10.9 Patent Portfolio: Emerging Focus Areas
Figure 10.10 Leading Players: Distribution by Number of Patents
Figure 10.11 Patent Portfolio: Benchmarking by Patent Characteristics
Figure 10.12 Patent Portfolio: Benchmarking by International Patents
Figure 10.13 Patent Portfolio: Distribution by Geographical Region and Patent Type
Figure 10.14 Non-Viral Transfection Systems: Age of Patents
Figure 10.15 Patent Portfolio: Valuation Analysis
Figure 11.1 Publication Analysis: Cumulative Distribution by Year of Publication, 2014-2019
Figure 11.2 Publication Analysis: Distribution by Publication Focus
Figure 11.6 Publication Analysis: Distribution by Type of Molecule Delivered
Figure 11.3 Publication Analysis: Distribution by Target Therapeutic Area
Figure 11.4 Publication Analysis: Important Cell Types Evaluated
Figure 11.5 Publication Analysis: Important Cell Lines Evaluated
Figure 11.7 Leading Players: Geographical Distribution by Number of Publications
Figure 11.8 Key Journals: Distribution by Number of Publications
Figure 12.1 Overall Non-Viral Transfection Systems Market, 2020-2030 (USD Million)
Figure 12.2 Non-Viral Transfection Systems Market: Distribution by Transfection Method,
2020 and 2030 (USD Million)
Figure 12.3 Non-Viral Transfection Systems Market: Distribution by End-User, 2020 and 2030 (USD Million)
Figure 12.4 Non-Viral Transfection Systems Market: Distribution by Area of Application, 2020 and 2030 (USD Million)
Figure 12.5 Non-Viral Transfection Systems Market: Distribution by Regions, 2020 and 2030
(USD Million)
Figure 12.6 Non-Viral Transfection Systems Market in North America, 2020-2030 (USD
Million)
Figure 12.7 Non-Viral Transfection Systems Market in North America: Share of Pharmaceutical Companies, 2020-2030 (USD Million)
Figure 12.8 Non-Viral Transfection Systems Market in North America: Share of Academic and Research Institutions, 2020-2030 (USD Million)
Figure 12.9 Non-Viral Transfection Systems Market in North America: Share of Other End-Users, 2020-2030 (USD Million)
Figure 12.10 Non-Viral Transfection Systems Market in North America for Research Application, 2020-2030 (USD Million)
Figure 12.11 Non-Viral Transfection Systems Market in North America for Clinical Application, 2020-2030 (USD Million)
Figure 12.12 Non-Viral Transfection Systems Market in Europe, 2020-2030 (USD Million)
Figure 12.13 Non-Viral Transfection Systems Market in Europe: Share of Pharmaceutical Companies, 2020-2030 (USD Million)
Figure 12.14 Non-Viral Transfection Systems Market in Europe: Share of Academic and Research Institutions, 2020-2030 (USD Million)
Figure 12.15 Non-Viral Transfection Systems Market in Europe: Share of Other End-Users, 2020-2030 (USD Million)
Figure 12.16 Non-Viral Transfection Systems Market in Europe for Research Application, 2020-2030 (USD Million)
Figure 12.17 Non-Viral Transfection Systems Market in Europe for Clinical Application, 2020-2030 (USD Million)
Figure 12.18 Non-Viral Transfection Systems Market in Asia-Pacific, 2020-2030 (USD
Million)
Figure 12.19 Non-Viral Transfection Systems Market in Asia-Pacific: Share of Pharmaceutical Companies, 2020-2030 (USD Million)
Figure 12.20 Non-Viral Transfection Systems Market in Asia-Pacific: Share of Academic and Research Institutions, 2020-2030 (USD Million)
Figure 12.21 Non-Viral Transfection Systems Market in Asia-Pacific: Share of Other End-Users, 2020-2030 (USD Million)
Figure 12.22 Non-Viral Transfection Systems Market in Asia-Pacific for Research Application, 2020-2030 (USD Million)
Figure 12.23 Non-Viral Transfection Systems Market in Asia-Pacific for Clinical Application, 2020-2030 (USD Million)
Figure 12.24 Non-Viral Transfection Systems Market in Rest of the World, 2020-2030 (USD
Million)
Figure 12.25 Non-Viral Transfection Systems Market in Rest of the World: Share of Pharmaceutical Companies, 2020-2030 (USD Million)
Figure 12.26 Non-Viral Transfection Systems Market in Rest of the World: Share of Academic and Research Institutions, 2020-2030 (USD Million)
Figure 12.27 Non-Viral Transfection Systems Market in Rest of the World: Share of Other End-Users, 2020-2030 (USD Million)
Figure 12.28 Non-Viral Transfection Systems Market in Rest of the World for Research Application, 2020-2030 (USD Million)
Figure 12.29 Non-Viral Transfection Systems Market in Rest of the World for Clinical Application, 2020-2030 (USD Million)
LIST OF TABLES
Table 3.1. Specifications of Viral Vectors
Table 4.1. Non-Viral Transfection Reagents: Information on Type of Carrier,
Recommended Cell Type, Transfection Efficiency and Volume of Reagent
Table 4.2. Non-Viral Transfection Reagents: Information on Storage Requirements, Serum Compatibility, Type of Molecule Delivered and Cost of System
Table 4.3. Non-Viral Transfection Reagent Developers: List of Companies
Table 4.4. Electroporation-based Transfection Systems: Information on Recommended Cell Type and Type of Molecule Delivered
Table 4.5. Electroporation-based Transfection Systems: Information on Pulse Time, Compatible Cell Type and Output Voltage
Table 4.6. Electroporation-based Transfection System Developers: List of Companies
Table 4.7. Other Non-Viral Transfection Systems: Information on Recommended Cell Type, Type of Molecule Delivered and Compatible Cell Type
Table 4.8. Other Non-Viral Transfection System Developers: List of Companies
Table 6.1. Altogen Biosystems: Company Snapshot
Table 6.2. Altogen Biosystems: Future Outlook
Table 6.3. Millipore Sigma: Company Snapshot
Table 6.4. Millipore Sigma: Future Outlook
Table 6.5. OZ Biosciences: Company Snapshot
Table 6.6. OZ Biosciences: Future Outlook
Table 6.7. Thermo Fisher Scientific: Company Snapshot
Table 6.8. Thermo Fisher Scientific: Future Outlook
Table 6.9. Bio-Rad Laboratories: Company Snapshot
Table 6.10. Bio-Rad Laboratories: Future Outlook
Table 6.11. Ningbo Scientz Biotechnology: Company Snapshot
Table 6.12. BEX: Company Snapshot
Table 6.13. BTX: Company Snapshot
Table 6.14. MaxCyte: Company Snapshot
Table 6.15. MaxCyte: Future Outlook
Table 6.16. NepaGene: Company Snapshot
Table 6.17. Celsion Corporation: Company Snapshot
Table 6.18. Celsion Corporation: Future Outlook
Table 6.19. Genprex: Company Snapshot
Table 6.20. Genprex: Future Outlook
Table 6.21. Inovio Pharmaceuticals: Company Snapshot
Table 6.22. Inovio Pharmaceuticals: Future Outlook
Table 7.1. Industry Players in North America: Most Likely Partners
Table 7.2. Industry Players in North America: Likely Partners
Table 7.3. Industry Players in North America: Less Likely Partners
Table 7.4. Non-Industry Players in North America: Most Likely Partners
Table 7.5. Non-Industry Players in North America: Likely Partners
Table 7.6. Non-Industry Players in North America: Less Likely Partners
Table 7.7. Industry Players in Europe: Most Likely Partners
Table 7.8. Industry Players in Europe: Likely Partners
Table 7.9. Industry Players in Europe: Less Likely Partners
Table 7.10. Non-Industry Players in Europe: Most Likely Partners
Table 7.11. Non-Industry Players in Europe: Likely Partners
Table 7.12. Non-Industry Players in Europe: Less Likely Partners
Table 7.13. Industry Players in Asia-Pacific: Most Likely Partners
Table 7.14. Industry Players in Asia-Pacific: Likely Partners
Table 7.15. Industry Players in Asia-Pacific: Less Likely Partners
Table 7.16. Non-Industry Players in Asia-Pacific: Most Likely Partners
Table 7.17. Non-Industry Players in Asia-Pacific: Likely Partners
Table 7.18. Non-Industry Players in Asia-Pacific: Less Likely Partners
Table 9.1. Clinical Trial Analysis: List of Phase IV Trials
Table 10.1. Patent Portfolio: CPC Symbols
Table 10.2. Patent Portfolio: Most Popular CPC Symbols
Table 10.3. Patent Portfolio: List of Top CPC Symbols
Table 10.4. Patent Valuation Analysis: Categorization based on Weighted Valuation Scores
Table 10.5. Patent Portfolio: List of Relatively Higher Value Patents
Table 15.1. Non-Viral Transfection Reagents: Distribution by Type of Carrier Used
Table 15.2. Non-Viral Transfection Reagents: Distribution by Type of Molecule Delivered
Table 15.3. Non-Viral Transfection Reagent Developers: Distribution by Year of Establishment
Table 15.4. Non-Viral Transfection Reagent Developers: Distribution by Company Size
Table 15.5. Non-Viral Transfection Reagent Developers: Distribution by Geography
Table 15.6. Electroporation-based Transfection Systems: Distribution by Type of Molecule Delivered
Table 15.7. Electroporation-based Transfection Systems: Distribution by Compatible
Cell Type
Table 15.8. Electroporation-based Transfection System Developers: Distribution by Year of Establishment
Table 15.9. Electroporation-based Transfection System Developers: Distribution by Company Size
Table 15.10. Electroporation-based Transfection System Developers: Distribution by Geography
Table 15.11. Other Non-Viral Transfection Systems: Distribution by Type of
Molecule Delivered
Table 15.12. Other Non-Viral Transfection Systems: Distribution by Compatible Cell Type
Table 15.13. Other Non-Viral Transfection System Developers: Distribution by Year of
Establishment
Table 15.14. Other Non-Viral Transfection System Developers: Distribution by Company
Size
Table 15.15. Other Non-Viral Transfection System Developers: Distribution by
Geography
Table 15.16. Millipore Sigma: Annual Revenues, 2013-Q3 2019 (USD Million)
Table 15.17. Thermo Fisher: Annual Revenues, 2013-2019 (USD Billion)
Table 15.18. Bio-Rad Laboratories: Annual Revenues, 2013-Q3 2019 (USD Million)
Table 15.19. MaxCyte: Annual Revenues, 2013-H1 2019 (USD Million)
Table 15.20. Genprex: Annual Revenues, 2013-Q3 2019 (USD Million)
Table 15.21. Inovio Pharmaceuticals: Annual Revenues, 2013-Q3 2019 (USD Million)
Table 15.22. Clinical Trial Analysis: Distribution by Trial Registration Year
Table 15.23. Clinical Trial Analysis: Distribution of Number of Patients Enrolled by Trial
Registration Year
Table 15.24. Clinical Trial Analysis: Distribution by Type of Trial Phase
Table 15.25. Clinical Trial Analysis: Distribution by Type of Trial Status
Table 15.26. Clinical Trial Analysis: Distribution by Type of Sponsor
Table 15.27. Clinical Trial Analysis: Distribution by Type of Therapy
Table 15.28. Clinical Trial Analysis: Distribution by Target Therapeutic Area
Table 15.29. Clinical Trial Analysis: Distribution by Type of Trial Design
Table 15.30. Clinical Trial Analysis: Distribution by Type of Patient Allocation Model Used
Table 15.31. Clinical Trial Analysis: Distribution by Type of Masking Adopted
Table 15.32. Clinical Trial Analysis: Distribution by Type of Intervention
Table 15.33. Clinical Trial Analysis: Distribution by Type of Trial Purpose
Table 15.34. Patent Portfolio: Distribution by Type of Patent
Table 15.35. Patent Portfolio: Cumulative Distribution by Publication Year, 2017-2019
Table 15.36. Patent Portfolio: Distribution by Geographical Location and Publication Year
Table 15.37. Patent Portfolio: Distribution by Patent Type and Publication Year
Table 15.38. Patent Portfolio: Distribution by Geographical Location
Table 15.39. Patent Portfolio: Distribution by Jurisdiction
Table 15.40. Patent Portfolio: Cumulative Year-wise Distribution by Type of Applicant
Table 15.41. Patent Portfolio: Leading Players by Number of Patents
Table 15.42. Patent Portfolio: Distribution by Geographical Region and Patent Type
Table 15.43. Publication Analysis: Cumulative Year-wise Trend, 2014-2019
Table 15.44. Publication Analysis: Distribution by Publication Focus
Table 15.45. Publication Analysis: Distribution by Type of Molecule Delivered
Table 15.46. Publication Analysis: Distribution by Target Therapeutic Area
Table 15.47. Key Journals: Distribution by Number of Publications
Table 15.48. Non-Viral Transfection Systems Market: Overall Market Opportunity, Conservative, Base and Optimistic Scenario, 2020-2030 (USD Million)
Table 15.49. Non-Viral Transfection Systems Market: Distribution by Transfection Method, Conservative, Base and Optimistic Scenario, 2020 and 2030 (USD Million)
Table 15.50. Non-Viral Transfection Systems Market: Distribution by End User, Conservative, Base and Optimistic Scenario, 2020 and 2030 (USD Million)
Table 15.51. Non-Viral Transfection Systems Market: Distribution by Area of Application, Conservative, Base and Optimistic Scenario, 2020 and 2030 (USD Million)
Table 15.52. Non-Viral Transfection Systems Market: Distribution by Region, Conservative, Base and Optimistic Scenario, 2020 and 2030 (USD Million)
Table 15.53. Non-Viral Transfection Systems Market in North America, Conservative, Base and Optimistic Scenario, 2020-2030 (USD Million)
Table 15.54. Non-Viral Transfection Systems Market in North America: Share of Pharmaceutical Companies, 2020-2030 (USD Million)
Table 15.55. Non-Viral Transfection Systems Market in North America: Share of Academic and Research Institutions, 2020-2030 (USD Million)
Table 15.56. Non-Viral Transfection Systems Market in North America: Share of Other End-Users, 2020-2030 (USD Million)
Table 15.57. Non-Viral Transfection Systems Market in North America for Research Application, 2020-2030 (USD Million)
Table 15.58. Non-Viral Transfection Systems Market in North America for Clinical Application, 2020-2030 (USD Million)
Table 15.59. Non-Viral Transfection Systems Market in Europe, Conservative, Base and Optimistic Scenario, 2020-2030 (USD Million)
Table 15.60. Non-Viral Transfection Systems Market in Europe: Share of Pharmaceutical Companies, 2020-2030 (USD Million)
Table 15.61. Non-Viral Transfection Systems Market in Europe: Share of Academic and Research Institutions, 2020-2030 (USD Million)
Table 15.62. Non-Viral Transfection Systems Market in Europe: Share of Other End-Users, 2020-2030 (USD Million)
Table 15.63. Non-Viral Transfection Systems Market in Europe for Research Application,
2020-2030 (USD Million)
Table 15.64. Non-Viral Transfection Systems Market in Europe for Clinical Application,
2020-2030 (USD Million)
Table 15.65. Non-Viral Transfection Systems Market in Asia-Pacific, Conservative, Base and Optimistic Scenario, 2020-2030 (USD Million)
Table 15.66. Non-Viral Transfection Systems Market in Asia-Pacific: Share of Pharmaceutical Companies, 2020-2030 (USD Million)
Table 15.67. Non-Viral Transfection Systems Market in Asia-Pacific: Share of Academic and Research Institutions, 2020-2030 (USD Million)
Table 15.68. Non-Viral Transfection Systems Market in Asia-Pacific: Share of Other End-Users, 2020-2030 (USD Million)
Table 15.69. Non-Viral Transfection Systems Market in Asia-Pacific for Research Application, 2020-2030 (USD Million)
Table 15.70. Non-Viral Transfection Systems Market in Asia-Pacific for Clinical Application, 2020-2030 (USD Million)
Table 15.71. Non-Viral Transfection Systems Market in Rest of the World, Conservative, Base and Optimistic Scenario, 2020-2030 (USD Million)
Table 15.72. Non-Viral Transfection Systems Market in Rest of the World: Share of Pharmaceutical Companies, 2020-2030 (USD Million)
Table 15.73. Non-Viral Transfection Systems Market in Rest of the World: Share of Academic and Research Institutions, 2020-2030 (USD Million)
Table 15.74. Non-Viral Transfection Systems Market in Rest of the World: Share of Other End-Users, 2020-2030 (USD Million)
Table 15.75. Non-Viral Transfection Systems Market in Rest of the World for Research Application, 2020-2030 (USD Million)
Table 15.76. Non-Viral Transfection Systems Market in Rest of the for World Clinical Application, 2020-2030 (USD Million)

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook